Please login to the form below
SNG001
This page shows the latest SNG001 news and features for those working in and with pharma, biotech and healthcare.
UK biotech Synairgen treats first patient in phase 3 COVID-19 trial
SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs. ... SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation.
Latest news
-
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. ... Further, 58% of the patients in the SNG001 group had recovered on day 28,
-
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... In exacerbating patients who already required treatment with
-
UK biotech Synairgen reveals promising early results for COVID-19 drug
The double-blind, placebo-controlled phase 1 trial of SNG001 recruited 101 hospitalised COVID-19 patients from nine hospital sites across the UK. ... While three patients died after being randomised to receive the placebo, no deaths were observed among
-
UK biotech Synairgen to begin COVID-19 trial of lead candidate
SNG001 (inhaled formulation of interferon-beta-1a), as concerns grow in the UK that COVID-19 cases could soar in the comings weeks. ... SNG001 delivers a formulation of INF-beta-1a to the lungs directly via nebulisation, and is suitable for inhaled
-
AZ licenses asthma infection drug from Synairgen
The novel formulation - called SNG001 - is designed to prevent the sometimes severe exacerbations suffered by asthma patients when they develop respiratory viral infections such as colds. ... The big pharma company will also meet all future development
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
UK biotech Synairgen reveals promising early results for COVID-19 drug
AZ licenses asthma infection drug from Synairgen
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
As the intense efforts to find a solution to COVID-19 finally start to bear fruit – with, for example, Synairgen showing promising results with SNG001 – how we’ve got here through ... in late March, when AIM-listed and Southampton-based Synairgen
-
Pharma deals during June 2014
Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001.
Well-funded life sciences firms are making long-term progress – and their investors are too
Pharma deals during June 2014
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
